Asset
AVORALSTAT
BIOCRYST PHARMACEUTICALS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02303626 | phase2_3 | completed | 2014-12-17 | 2016-01-01 | BioCryst Pharmaceuticals | 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks |
| NCT07228559 | phase1 | terminated | 2025-10-02 | 2026-04-17 | BioCryst Pharmaceuticals | A Study of Avoralstat In Participants With Diabetic Macular Edema |
| NCT02125162 | phase1 | completed | 2014-04-01 | 2014-07-01 | BioCryst Pharmaceuticals | A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161 |
| NCT02670720 | phase3 | terminated | 2015-12-01 | 2016-02-01 | BioCryst Pharmaceuticals | Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema |
| NCT01984788 | phase2 | completed | 2013-11-01 | 2014-05-01 | BioCryst Pharmaceuticals | Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE |
FDA applications (0)
This company has no applications containing this asset.